What's New: Drugs RSS Feed
- La FDA advierte del riesgo de sufrir daños hepáticos graves con los tratamientos de Viekira Pak y Technivie contra la hepatitis C February 26, 2021
- La FDA actualiza las etiquetas de los inhibidores del SGLT2 para la diabetes a fin de incluir advertencias sobre concentraciones de ácido demasiado altas en la sangre e infecciones graves del tracto urinario February 26, 2021
- Over-the-Counter (OTC) Drug Review | OTC Monograph Reform in the CARES Act February 26, 2021
- Over-The-Counter Monograph User Fee Program (OMUFA) February 26, 2021
- Drug Master File (DMF) and Drug Substance Question and Answer Webinar Following March 3-4, 2021 Workshop - 04/09/2021 - 04/09/2021 February 26, 2021
- User Fee Lists February 26, 2021
- What's New Related to Drugs February 26, 2021
- Generic Drug Facilities, Sites and Organization Lists February 26, 2021
- Public Notification: Vy & Tea contains hidden drug ingredient February 26, 2021
- Public Notification: Super Slim contains hidden drug ingredients February 26, 2021
What's new
- Human medicines European public assessment report (EPAR): Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, HIV Infections, Date of authorisation: 31/08/2014, Revision: 20, Status: Authorised February 26, 2021
- Human medicines European public assessment report (EPAR): Trimbow, beclometasone,formoterol,bromide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 17/07/2017, Revision: 4, Status: Authorised February 26, 2021
- SME and academia Clinical Trials Information System (CTIS) two-part training webinar - Day 1, Virtual event, from 22/02/2021 to 22/02/2021 February 26, 2021
- Human medicines European public assessment report (EPAR): Ogluo, glucagon, Diabetes Mellitus, Date of authorisation: 11/02/2021, Status: Authorised February 26, 2021
- Human medicines European public assessment report (EPAR): Pioglitazone Accord, pioglitazone, Diabetes Mellitus, Type 2, Date of authorisation: 21/03/2012, Revision: 6, Status: Authorised February 26, 2021
- Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Arthritis, Rheumatoid,Spondylitis, Ankylosing,Psoriasis,Arthritis, Psoriatic,Colitis, Ulcerative,Crohn Disease,Arthritis, Juvenile Rheumatoid,Hidradenitis Suppurativa,Uveitis, Date of authorisation: 11/02/2021, Status: Authorised February 26, 2021
- Human medicines European public assessment report (EPAR): Actos, pioglitazone, Diabetes Mellitus, Type 2, Date of authorisation: 13/10/2000, Revision: 26, Status: Authorised February 26, 2021